Google researchers propose a two-step method to make human translation evaluation more reliable — without doubling costs.
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback